SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors discuss the potential impact of a reported earnings miss, attributed to a tax dispute in Brazil, despite revenue being in line with expectations. Community members are debating whether this dip presents a buying opportunity or signals a larger correction for the streaming giant, with some questioning the company's valuation and future growth prospects in an increasingly competitive market.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is experiencing volatility as traders discuss the impact of a widespread AWS outage and its potential fallout, including possible lawsuits. The community is also weighing the implications of Anthropic choosing Google over Amazon for cloud computing needs, sparking debate about AWS's competitive positioning against $MSFT and $GOOGL. Despite these concerns, some investors view the dip as a buying opportunity, citing Amazon's strong market presence.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is experiencing a selloff, prompting discussions about potential manipulation and profit-taking after a significant run-up, with some community members pointing to broader sector weakness as a factor; despite the dip, bulls remain confident in the long-term prospects of IREN given its position in AI and data centers, while others express concerns over short-term volatility.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors assess the potential impact of OpenAI's browser and Google's AI initiatives, including a significant investment in Indian infrastructure. Community discussions revolve around whether the stock's recent pullback represents a buying opportunity amidst the evolving AI landscape and competition in search.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending due to a sector-wide selloff, sparking debates about potential manipulation and overbought conditions; the community is weighing whether this dip presents a buying opportunity, or signals further declines. Discussions also involve upcoming earnings and speculation around potential deals, particularly concerning AI data centers. Some traders are expressing concerns about dilution and the stock's correlation with Bitcoin's volatility.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending following its acquisition of Railbird, a prediction market platform, signaling a strategic move into regulated prediction markets beyond sports betting, stirring debate about its potential impact on DraftKings' standing with OSB states. The community is discussing whether this acquisition is a bold move towards sustainable growth or a reaction to competition, particularly from prediction markets like Polymarket and Kalshi, and its potential implications for expansion into untapped markets like California and Texas. Additionally, DraftKings' stock performance is being weighed against competitors like Robinhood, influencing community sentiment and investment strategies.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following its earnings report, with community chatter focused on procedure growth and the company's future outlook. While some express optimism about the robotic surgery market and potential for new all-time highs, others are concerned about margin pressures and valuation. Discussions also revolve around the impact of tariffs and expansion into international markets.

Alphabet Inc - Ordinary Shares - Class C

GOOG is seeing increased interest amid discussions about potential AI integrations and competition with other tech companies. Community members are debating the stock's valuation and future growth prospects in the AI landscape. The stock's recent price action and upcoming earnings are also focal points for traders.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending following its earnings report and subsequent guidance, which has led to significant discussion about the company's near-term outlook. Community members are debating whether the stock is oversold, with some pointing to broader sector concerns and potential trade tensions affecting future performance. Others suggest the dip presents a buying opportunity, citing the company's long-term fundamentals and dividend.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending after announcing a collaboration with OpenAI to develop custom AI chips, potentially bringing in billions in revenue and further solidifying its position in the AI infrastructure market. Community discussions highlight the significance of this deal, with some speculating on its impact on competitors and future growth potential for Broadcom. Investors are closely monitoring analyst upgrades and potential resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments

Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners The Institute for Follicular...

BeOne Medicines Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation...

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR  (ONC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?

Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Surges 4.0%: Is This an Indication of Further Gains?

BeOne Medicines Ltd. - Sponsored ADR  (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of Summit Therapeutics Inc. (SMMT) surged more than 21% on Wednesday and extended gains in after-hours trading, driven by encouraging results from a late-stage cancer drug trial.The company’s sponsor, Akeso, announced that a phase 3 trial evaluating Summit’s drug, ivonescimab, in combination with chemotherapy, met its primary endpoint of progression-free survival in patients with advanced squamous non-small cell lung cancer (NSCLC).Akeso conducted the study across multiple centers in China, comparing the combination against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.An independent data monitoring committee found that the ivonescimab arm demonstrated statistically significant and clinically meaningful improvement.Summit plans to present the full dataset from the trial at a major medical conference later this year.&nbsp;On Stocktwits, sentiment for Summit rose further within 'extremely bullish' levels amid a 507% spike in 24-hour message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SMMT_sentiment_and_message_volume_as_of_April_23_png_a70ccf1959.webp" alt="SMMT sentiment and message volume as of April 23.png" width="1318" height="316"><figcaption>SMMT sentiment and message volume as of April 23. | source: Stocktwits</figcaption></figure>One bullish watcher urged investors to watch out for a "short squeeze up to $40."<stembedurl>https://stocktwits.com/BooEmmy/message/612403946</stembedurl>"The path is rising. And the journey has only just begun," said another.<stembedurl>https://stocktwits.com/Teluride/message/612467520</stembedurl>Summit is enrolling patients in a separate multiregional study pitting the same combination against pembrolizumab (Merck's Keytruda) plus chemo in first-line metastatic NSCLC. Early trial results from China have already shown promising results.The company also boosted investor enthusiasm after joining a clinical trial&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smmt-retail-chatter-explodes-on-pfizer-trial-pact/chdEqVTRx8">collaboration</a> with Pfizer in February.Summit's stock has surged by over 84% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Equity

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.


BeiGene to Present at Upcoming Investor Conferences

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside...

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial...

<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio shares</a> surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks&nbsp;while lifting retail sentiment.The clinical-stage immunotherapy company announced a collaboration and supply agreement with BeiGene to conduct a confirmatory Phase 3 clinical trial.&nbsp;The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for patients with advanced or metastatic non-small cell lung cancer who have developed resistance to immune checkpoint inhibitor therapy.According to ImmunityBio, multiple Phase 1 and 2 studies have already shown prolonged overall survival with this combination compared to historical chemotherapy results in similar patients.&nbsp;The upcoming Phase 3 trial, conducted globally across multiple sites, will enroll 462 participants. The primary endpoint is overall survival, while secondary measures include disease control rate, progression-free survival, objective response rate, and safety.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IBRX_sentiment_and_message_volume_Jan_29_015db24b68.png" alt="IBRX sentiment and message volume Jan 29.png" width="1318" height="324"><figcaption>IBRX sentiment and message volume Jan 29 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘bullish’ for ImmunityBio on Wednesday, up from ‘neutral’ a day ago, while BeiGene’s sentiment shifted to ‘extremely bullish’ amid a spike in message volume.&nbsp;One user speculated that BeiGene could also become ImmunityBio’s global partner for bladder cancer treatments, suggesting another announcement might follow soon.&nbsp;<stembedurl>https://stocktwits.com/Dmck9/message/601987411</stembedurl>Another post predicted a 150% rally in the coming weeks.<stembedurl>https://stocktwits.com/Terrashae/message/601984996</stembedurl>ImmunityBio has been a closely watched stock among retail traders, with its Stocktwits following growing by nearly 43% in the past year despite a 10% decline in the stock’s price over the same period.&nbsp;Year to date, however, shares are up nearly 28%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

BeOne Medicines Ltd - ADR

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$315.74
Prev Close	$318.59
Open	$317.04
Dividend Yield	0.00%
50-Day Moving Average	$324.71
Beta	0.68
Avg. Volume	336,581.57
PE Ratio	-185.47

52-Week High	$355.30
52-Week Low	$170.99
Market Capitalization	$302.75B
EPS (Annual)	-$6.13
Price to Book	9.28
Revenue Per Employee	$346,559.28
Enterprise Value/EBITDA	N/A

ONC
BeiGene Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ONC News

ONCBeiGene Ltd - ADR